Gut Permeability, Sensitivity and Symptomatology
Not Applicable
Completed
- Conditions
- Visceral HypersensitivityIrritable Bowel Syndrome
- Registration Number
- NCT02358564
- Lead Sponsor
- Mayo Clinic
- Brief Summary
To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of irritable bowel syndrome (IBS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mean Percent of complete epithelial cell loss 72 hours
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link gut permeability to visceral hypersensitivity in IBS patients?
How does the gastrointestinal permeability test in NCT02358564 compare to standard-of-care diagnostics for IBS?
Are biomarkers like zonulin or occludin useful for predicting IBS symptom exacerbation post-meals?
What adverse events are associated with rectal barostat procedures in IBS research and how are they managed?
How do fat infusion protocols in NCT02358564 relate to other IBS treatments targeting gut barrier function?
Trial Locations
- Locations (2)
Mayo Clinic in Florida
🇺🇸Jacksonville, Florida, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Mayo Clinic in Florida🇺🇸Jacksonville, Florida, United States